Juan Manuel Ferrero-Cafiero

6PUBLICATIONS
74CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Tomás Pascual, Maria Vidal, Juan M Cejalvo

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Dec 03, 2025
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa

|Dec 01, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.

Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa

|Jan 17, 2025
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.

Maria Vidal, Claudette Falato, Tomás Pascual

|Jul 11, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.

Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato

Pageof 1

Frequent Collaborators

6 joint publications

Tomás Pascual

5 joint publications

Aleix Prat

4 joint publications

Maria Vidal

4 joint publications

Mafalda Oliveira